Bio 2006 Analysts Predict Small-Cap Biotechs to Outperform Large-Caps This Year
13 Abril 2006 - 12:13PM
Business Wire
Samaritan Pharmaceuticals Inc. (AMEX:LIV) -- David W. Munno,
Merrill Lynch VP of biotechnology, stated, "Large-cap biotech firms
need some blockbuster products for meaningful growth which is more
than likely to come from small- to mid-sized biotechs." -- Vinny
Jindal, of Think Equity Partners LLC, stated, "Small-cap biotech is
going to have a banner year." Samaritan Pharmaceuticals Inc., a
developer of innovative drugs, announced today that biotech
analysts at Bio 2006 in Chicago, the industry's largest conference,
predicted encouraging trends for small-caps like Samaritan. Dr.
Greeson, CEO of Samaritan, stated, "We found a much stronger
interest in our blockbuster technology than ever before at Bio
2006, which we think might confirm the analyst predictions that
large-caps need product. We also found a warm reception to explore
in-licensing opportunities to market and distribute niche products
in Greece and Eastern Europe. We are extremely pleased with the
interest we have garnered." Samaritan Pharmaceuticals: "We
LIV....to Save Lives." Samaritan is a small-cap biotech, driven to
discover, develop, and commercialize, innovative therapeutics for
AIDS, Alzheimer's, cancer and heart disease. Look at
www.samaritanpharma.com. Please register on our Web site so we can
notify you of upcoming conference calls, news and events.
Disclaimer The company disclaims any information that is created by
an outside party and endorses only information that is communicated
by its press releases, filings and Web site. This news release
contains forward-looking statements that reflect management's
current beliefs about the potential for its drug candidates,
science and technology. However, as with any biopharmaceutical
under development, there are significant risks and uncertainties in
the process of development and regulatory review. There are no
guarantees that products will prove to be commercially successful.
For additional information about the factors that affect the
company's business, please read the company's latest Form 10-K
filed April 15, 2005. The company undertakes no duty to update
forward-looking statements.
Emles at Home ETF (AMEX:LIV)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Emles at Home ETF (AMEX:LIV)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
Real-Time news about Emles at Home ETF (American Stock Exchange): 0 recent articles
Más de Samaritan Pharmaceuticals Inc. ArtÃculos de Noticias